BrUOG IN THE NEWS
BrUOG IN THE NEWS:
BrUOG's Medical Director Answers 5 Questions
BRUOG's 20th Anniversary: 2014
For 20 years BrUOG has provided the administrative and financial infrastructure (a new walk-a-thon takes place May 4) for Rhode Island cancer specialists to develop and test their best ideas for fighting the disease in its many forms.
Farrah Fawcett Foundation Announces $50,000 Grant To Brown University Oncology Research Group
The BrUOG 276 study is investigating whether the addition of the immunotherapy drug, ADXS11-001, provided by Advaxis, Inc ADXS +7.71% , can be tolerated and if it will increase response rates when added to the standard care treatment of chemotherapy and radiation. While almost all anal cancers are HPV positive, Advaxis's immunotherapy drug "stimulates a person's immune system to assist in the attack of cells made cancerous by HPV," stated Howard Safran, MD, Medical Director of BrUOG and Professor of Medicine at The Warren Alpert Medical School of Brown University. After Advaxis showed promise in a Phase II cervical cancer trial, BrUOG is optimistic about the applicability of this treatment regimen in anal cancer.